SAR405: Selective ATP-Competitive Vps34 Inhibitor for Precision Autophagy Inhibition

Executive Summary: SAR405 is a potent and selective ATP-competitive inhibitor of Vps34, a class III PI3K, with a dissociation constant (Kd) of 1.5 nM and IC50 of 1 nM for human recombinant Vps34 enzyme (APExBIO). SAR405 exhibits no measurable inhibition of class I/II PI3Ks or mTOR at concentrations up to 10 μM, demonstrating exceptional selectivity (APExBIO). By targeting the ATP binding cleft of Vps34, SAR405 impairs late endosome-lysosome function, leading to autophagosome formation blockade and lysosome dysfunction (Mizoribine). Synergistic effects are observed when combined with mTOR inhibitors, such as everolimus, in cellular models (Park et al., 2023). SAR405 provides a validated pharmacological tool for dissecting the Vps34 kinase signaling pathway in cancer and neurodegenerative disease research (Vatalis.info).

Biological Rationale

Autophagy is a critical catabolic process for cellular homeostasis, particularly under energy stress and nutrient deprivation (Park et al., 2023). The class III phosphoinositide 3-kinase, Vps34, is essential for autophagosome initiation and vesicle trafficking (APExBIO). Recent studies have redefined the regulatory role of AMPK in autophagy, revealing that AMPK can suppress autophagy initiation by inhibiting ULK1 kinase activity, rather than promoting it as previously thought (Park et al., 2023). Pharmacological inhibition of Vps34 provides a means to dissect autophagic flux independent of AMPK-mTOR signaling, clarifying the specific contribution of Vps34 to autophagosome formation and lysosomal function (Mizoribine.com).

Mechanism of Action of SAR405

SAR405 is an ATP-competitive inhibitor that selectively targets the ATP binding cleft of Vps34, blocking its kinase activity (APExBIO). This inhibition disrupts the generation of phosphatidylinositol 3-phosphate (PI3P), an essential lipid for autophagosome nucleation and vesicular trafficking. In cell-based assays, SAR405 treatment leads to the accumulation of swollen late endosome-lysosomes and defective cathepsin D maturation, indicating compromised lysosomal function (Mizoribine). SAR405 blocks autophagosome formation in GFP-LC3 HeLa and H1299 cell lines, representing a direct and quantifiable blockade of autophagic flux (Park et al., 2023). Notably, SAR405 does not inhibit class I/II PI3Ks or mTOR, even at micromolar concentrations, minimizing off-target effects and confounding variables associated with broader PI3K inhibition (APExBIO).

Evidence & Benchmarks

• SAR405 exhibits a measured Kd of 1.5 nM and IC50 of 1 nM against purified human recombinant Vps34 enzyme in biochemical assays (APExBIO).
• No inhibition of class I or II PI3Ks, nor mTOR, is observed up to 10 μM SAR405 in kinase selectivity panels (APExBIO).
• SAR405 impairs autophagosome formation and blocks autophagic flux in GFP-LC3 HeLa and H1299 cell models, with visible accumulation of autophagy substrates (Park et al., 2023).
• Co-administration with mTOR inhibitors (e.g., everolimus) results in synergistic autophagy blockade and enhanced impairment of lysosomal function (Park et al., 2023).
• SAR405’s impact on late endosome-lysosome morphology and cathepsin D maturation has been confirmed via immunofluorescence and protease activity assays (Mizoribine.com).
• Experimental workflows using SAR405 demonstrate high reproducibility and compatibility with real-time imaging, immunoblotting, and vesicle tracking protocols (Vatalis.info).

Applications, Limits & Misconceptions

SAR405 is widely employed in cancer research and neurodegenerative disease models to interrogate autophagy inhibition and vesicle trafficking modulation (Vatalis). By enabling precise Vps34 kinase signaling pathway inhibition, SAR405 helps dissect the relative contributions of autophagy and lysosomal pathways to disease phenotypes. It is also used to validate hypotheses about lysosome function impairment in response to pharmacological intervention.

Common Pitfalls or Misconceptions

• SAR405 does not inhibit class I/II PI3Ks or mTOR: Off-target inhibition is negligible even at 10 μM (APExBIO).
• SAR405 is not effective in water-based solutions: It is highly soluble in DMSO (>10 mM), insoluble in water, and requires ultrasonic assistance for ethanol solutions (APExBIO).
• Long-term storage of working solutions reduces efficacy: Stock solutions should be stored below -20°C and working solutions should be prepared fresh (APExBIO).
• SAR405 does not address energy stress-mediated autophagy regulation: It specifically inhibits Vps34-dependent autophagosome formation, independent of AMPK/ULK1-mediated signaling (Park et al., 2023).
• Not a universal autophagy inhibitor: SAR405 targets class III PI3K only and does not affect other autophagy regulatory pathways (APExBIO).

This article extends the mechanistic depth of SAR405 and the New Paradigm of Vps34 Inhibition in Autophagy by explicitly integrating recent AMPK-ULK1 signaling insights and clarifying SAR405's selectivity boundaries. For practical laboratory guidance, see SAR405 (SKU A8883): Precision Vps34 Inhibition for Reliable Autophagy Assays—this article provides updated selectivity and workflow integration details. For a strategic, translational research perspective, SAR405 and the New Paradigm in Autophagy Research discusses deployment in advanced disease models—our article adds quantitative performance and current signaling context.

Workflow Integration & Parameters

• Solubility and Preparation: SAR405 is highly soluble in DMSO (>10 mM) and ethanol (with ultrasonic assistance), but insoluble in water (APExBIO).
• Storage: Stock solutions should be kept below -20°C for several months. Avoid repeated freeze-thaw cycles and do not store diluted solutions long-term (APExBIO).
• Recommended Concentrations: Effective cellular inhibition is typically observed at 10–500 nM; biochemical assays employ 1–100 nM (APExBIO).
• Assays: Compatible with immunoblotting, immunofluorescence, vesicle trafficking assays, live-cell imaging, and autophagic flux quantification (Vatalis.info).
• Controls: Use class I/II PI3K inhibitors and mTOR inhibitors to confirm specificity of observed phenotypes.

For further details and to obtain the validated SAR405 reagent (SKU A8883), refer to the APExBIO SAR405 product page.

Conclusion & Outlook

SAR405 delivers robust, selective Vps34 kinase inhibition, enabling high-confidence dissection of autophagy and vesicle trafficking pathways. Its unique selectivity profile and compatibility with diverse assay systems make it a gold standard tool for mechanistic studies in cancer and neurodegenerative disease models. Recent AMPK-ULK1 signaling discoveries underscore the need for pathway-specific interventions—SAR405’s action is pathway-restricted and allows clean experimental separation of Vps34-dependent autophagy inhibition from energy stress responses (Park et al., 2023). As research advances, SAR405 will remain central to autophagy research, disease modeling, and therapeutic exploration.